WEST DES MOINES, IA , United States, via ETELIGIS INC., 10/01/2014 - - Spotlight Innovation Inc. (OTCQB: STLT), has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.

"We are very pleased to be teaming with Mr. Cirino and look forward to benefiting from his strategic thinking, critical insights, and expertise," said Cris Grunewald, Chief Executive Officer and President of Spotlight Innovation. "Given his vast executive experience with multimillion dollar companies in the medical field, Mr. Cirino will be instrumental in assisting in the formulation and execution of strategies that will support our business development and growth objectives. Mr. Cirino has demonstrated industry leadership, knowledge and expertise."

Mr. Cirino is a healthcare technology executive with an extensive background in medical devices, distribution and healthcare information. His experience includes holding senior level management positions in several medical companies where he managed complex growth, integration and global operations. Mr. Cirino's considerable healthcare sector experience includes Chairman and CEO of Reichert Technologies, and President and CEO of Heartland Information Services, Imalux Corporation, and SourceOne Healthcare Technologies. Mr. Cirino holds an M.B.A., has completed advanced negotiating and corporate board effectiveness programs at Harvard Law School and Harvard Business School respectively, and was conferred the honorary degree of Doctor of Humane Letters by Lake Erie College in 2005.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation's leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With our support, development resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT:

Press Contact

Rene Erickson

Spotlight Innovation Inc.

1-515-274-9087

corpcomm@spotlightinnovation.com

Investor Relations Contact

Mike Reysack

Spotlight Innovation Inc.

1-641-512-1035

investor.relations@spotlightinnovation.com

Source: Spotlight Innovation Inc.

Associated Documentation:
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27984 - Link to submission on http://www.eteligis.com
http://www.eteligis.com/FileHandler.aspx?submissionRequest=27984&documentRequest=18354 - STLT_10-1-2014_PAP_ETL.doc